Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Based on the populations studied in clinical trials to date, retatrutide has been investigated primarily in adults living with obesity defined as a body mass index (BMI) of 30 kg/m or above as well as in those who are overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia
Australian and New Zealand journal of medicine
Gradual Increases : Doses are adjusted over weeks based on individual tolerance and progress, under medical supervision
Visible weight loss begins appearing around weeks 6-8 as cumulative loss reaches 8-12 pounds
This product is supplied exclusively for laboratory, scientific, and analytical research
Particle sizes were optimized, with some as low as 1103 nm and a uniformity (PDI) as tight as 0.084 in certain batches
